Fig. 1. Clinical manifestations at the first visit
a, b) Macroscopic findings. Multiple areas of erythema measuring 1-10 cm in diameter are evident. c) Histopathological findings of the erythema (hematoxylin-eosin stain, ×200). Small-sized atypical lymphocyte-like hyperchromatic cells with haloes had infiltrated into the epidermis and upper dermis in a scattered manner.
Fig. 2. Clinical manifestations during the course of the disease
a) Macroscopic findings at two years after the first visit. Two ulcerative tumors are evident on MF patch-lesions of the left chest.b) Histopathological findings of the tumor (hematoxylin-eosin stain, loupe image). Nodular infiltration of tumor cells is evident in the dermis and subcutis. c) Histopathological findings of the tumor (hematoxylin-eosin stain, ×400). Some nests consist of anaplastic large cells. d) Histopathological findings of the tumor (hematoxylin-eosin stain, ×400). Small-sized atypical lymphocyte-like hyperchromatic cells have proliferated in the tumor. e)Immunohistochemical examination of the tumor using anti-CD30 antibody (Roche, Basel, Switzerland) (loupe image). Anti-CD30 antibodies are reactive to nearly half of the cells in the tumor. f)Immunohistochemical examination using anti-CD30 antibody (×400). Anti-CD30 antibodies are reactive to anaplastic large cells. g)Immunohistochemical examination using anti-CD30 antibody (×400). Anti-CD30 antibodies are not reactive to small atypical cells.h) Immunohistochemical examination using anti-CXCR3 antibody (R&D systems, Minneapolis, MN) (×100). Anti-CXCR3 antibodies are reactive to anaplastic large cells. i) Immunohistochemical examination using anti-CCR3 antibody (R&D systems) (×100). Anti-CCR3 antibodies are not reactive to anaplastic large cells. j)Macroscopic findings at 3 months after the initial appearance of the tumors. The tumors regressed spontaneously, leaving scars.